Free Radical Research in Cancer
Cancer is a great challenge to efficient therapy due to biological diversity. Disturbed oxidative homeostasis in cancer cells certainly contributes to differential therapy response. Further, one of the hallmarks of cancer cells is adaptation which includes fine tuning of the cellular metabolic and s...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Book Chapter |
| Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2020
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04171naaaa2201021uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_68644 | ||
| 005 | 20210501 | ||
| 020 | |a books978-3-03936-089-5 | ||
| 020 | |a 9783039360888 | ||
| 020 | |a 9783039360895 | ||
| 024 | 7 | |a 10.3390/books978-3-03936-089-5 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 072 | 7 | |a TB |2 bicssc | |
| 100 | 1 | |a Čipak Gašparović, Ana |4 edt | |
| 700 | 1 | |a Čipak Gašparović, Ana |4 oth | |
| 245 | 1 | 0 | |a Free Radical Research in Cancer |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2020 | ||
| 300 | |a 1 electronic resource (192 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Cancer is a great challenge to efficient therapy due to biological diversity. Disturbed oxidative homeostasis in cancer cells certainly contributes to differential therapy response. Further, one of the hallmarks of cancer cells is adaptation which includes fine tuning of the cellular metabolic and signalling pathways as well as transcription profiles. There are several factors which contribute to the tumor diversity and therapy response, and oxidative stress is certainly one of them. Changes in oxygen levels due to hypoxia/reoxygenation during tumor growth modulate antioxidative patterns finally supporting increased cell diversity and adaptation to stressing conditions. Additionally, cancer chemotherapy based on ROS production can also induce also adaptation. To counteract these negative effects natural products are often used for their antioxidant activities as well as photodynamic therapy supported by novel chemosensitizers. Understanding of possible pathways which can trigger antioxidant defence at a certain time during cancer development can also provide possible strategies in fighting cancer. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Technology: general issues |2 bicssc | |
| 653 | |a NQO1 | ||
| 653 | |a NQO1*2 | ||
| 653 | |a polymorphism | ||
| 653 | |a quinone | ||
| 653 | |a breast cancer | ||
| 653 | |a menadione | ||
| 653 | |a lapachone | ||
| 653 | |a doxorubicin | ||
| 653 | |a ascorbate | ||
| 653 | |a oxidative stress | ||
| 653 | |a reactive oxygen species | ||
| 653 | |a sperm | ||
| 653 | |a cancer chemotherapy | ||
| 653 | |a antioxidant therapy | ||
| 653 | |a antioxidant proteins | ||
| 653 | |a chemoresistance | ||
| 653 | |a oxaliplatin | ||
| 653 | |a 5-Fluorouracil | ||
| 653 | |a myelodysplastic syndromes | ||
| 653 | |a carbonylation | ||
| 653 | |a deferasirox | ||
| 653 | |a ovary | ||
| 653 | |a calcium channel | ||
| 653 | |a Trolox | ||
| 653 | |a granulosa cell tumor | ||
| 653 | |a cell death | ||
| 653 | |a mitochondria | ||
| 653 | |a photodynamic therapy | ||
| 653 | |a singlet oxygen | ||
| 653 | |a nitric oxide | ||
| 653 | |a light | ||
| 653 | |a combination therapy | ||
| 653 | |a antioxidants | ||
| 653 | |a bleomycin | ||
| 653 | |a cancer treatment | ||
| 653 | |a chemotherapy-induced toxicity | ||
| 653 | |a cisplatin | ||
| 653 | |a free radicals | ||
| 653 | |a methotrexate | ||
| 653 | |a ozone therapy | ||
| 653 | |a lung cancer | ||
| 653 | |a cancer metabolism | ||
| 653 | |a reactive oxygen species (ROS) | ||
| 653 | |a therapy resistance | ||
| 653 | |a new therapeutic strategies | ||
| 653 | |a breast cancer stem cells | ||
| 653 | |a 4-hydroxy-2-nonenal | ||
| 653 | |a extracellular matrix | ||
| 653 | |a NRF2 | ||
| 653 | |a bardoxolone methyl | ||
| 653 | |a prostate cancer | ||
| 653 | |a castration-resistant prostate cancer | ||
| 653 | |a androgen receptor (AR), AR-V7 | ||
| 653 | |a anti-androgen | ||
| 653 | |a enzalutamide | ||
| 653 | |a androgen deprivation therapy | ||
| 653 | |a cancer | ||
| 653 | |a antioxidant | ||
| 653 | |a triphala | ||
| 653 | |a ayurveda | ||
| 653 | |a chemoprevention and chemotherapy | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/2406 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/68644 |7 0 |z DOAB: description of the publication |